Biofrontera to present at Lytham Partners Fall 2025 Investor Conference.

Biofrontera Inc. will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Fall 2025 Investor Conference on September 30, 2025. The webcast presentation will be available at 1:15 p.m. ET, and one-on-one meetings can be arranged by contacting Lytham Partners.

Biofrontera Inc. (NASDAQ: BFRI), a biopharmaceutical company specializing in dermatological products, has announced its participation in the upcoming Lytham Partners Fall 2025 Investor Conference on September 30, 2025. The company will deliver a webcast presentation at 1:15 p.m. ET and conduct one-on-one meetings with investors throughout the virtual event.

The webcast presentation will take place at 1:15 p.m. ET on Tuesday, September 30, 2025. Investors can access the webcast through the conference website or directly via the provided link, with replay available after the event. The webcast can be accessed by visiting the conference home page at [https://lythampartners.com/fall2025/](https://lythampartners.com/fall2025/) or directly at [https://app.webinar.net/wWqPp4Yr0kD](https://app.webinar.net/wWqPp4Yr0kD).

Management will be participating in virtual one-on-one meetings throughout the event. To arrange a meeting with management, please contact Lytham Partners at 1x1@lythampartners.com or register for the event at [https://lythampartners.com/fall2025invreg/](https://lythampartners.com/fall2025invreg/).

Biofrontera Inc. focuses on the development and treatment of dermatological conditions, with a particular emphasis on Photodynamic Therapy (PDT). The company commercializes the drug-device combination Ameluz ® with the RhodoLED ® lamp series for PDT of actinic keratosis (AK), pre-cancerous skin lesions, which may progress to invasive skin cancers. Additionally, Biofrontera conducts clinical trials to extend the use of its products to treat non-melanoma skin cancers and moderate to severe acne. For more information, visit [www.biofrontera-us.com](https://www.biofrontera-us.com) and follow Biofrontera on LinkedIn and X.

Investor Relations Contact:
Ben Shamsian
Lytham Partners
646-829-9701